We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » GSK’s Blenrep Approved for Multiple Myeloma
The FDA has approved GlaxoSmithKline’s Blenrep (belantamab mafodotin-blmf) for the treatment of adults with elapsed or refractory multiple myeloma who have received at least four prior therapies.